

New York State Cancer Registry

Guide to Determine Reportability for Physician Medical Practices

This guide provides a list of diagnoses reportable to the NYS Cancer Registry. Note that there are some ICD-9-CM codes that include multiple terms (conditions); some are reportable and some are not reportable. For example, the category for 288.4 (ICD-9-CM) is “Hemaphagocytic syndromes;” however, only the conditions listed in that section below are reportable. Information provided in the Notes/Instructions column refers to completing the electronic case report form of the Physician Cancer Reporting web application on the Health Commerce System.

If you have any questions about determining reportability or selecting the best primary site or histology in the web application, call your field representative at the Cancer Registry at 518-474-0971 for assistance.

ICD-9-CM	Diagnostic Term	Notes/Instructions
140.0 – 208.9	Malignant neoplasms Note: 173x basal or squamous skin cancer is not reportable	Use cancer-specific modules for melanoma, prostate cancer, lymphoma, leukemia, and other hematopoietic malignancies. For all other cancers, use the “Other Cancer” module and select the most specific cancer site and histology possible. The cancer site listing begins with the digestive system (lip), continues down to other systems, and ends with the brain and eyes.
209.00-209.30	Neuroendocrine tumors Malignant carcinoid tumors	
209.31-209.36	Merkel cell carcinoma	Use the Other Cancer module and select “Skin-nonepithelial-No Melanoma” for the primary site and “Merkel cell carcinoma” for the histology.
209.70-209.79	Secondary neuroendocrine tumor	
225.0 – 225.9	Benign neoplasms of brain and other parts of nervous system	All tumors in this ICD-9-CM range are reportable.
227.3	Benign neoplasms of pituitary gland and craniopharyngeal duct	For craniopharyngeal duct tumors, select “Other endocrine including thymus” as the primary site of cancer.
227.4	Benign neoplasms of pineal gland	For pineal gland tumors, select “Other endocrine including thymus” as the primary site of cancer.
228.02	Hemangioma of intracranial structures	
230.0 – 234.9	Carcinoma in situ Note: in situ carcinoma of cervix (233.1) is not reportable	
237.0	Neoplasm of uncertain behavior (borderline) of the pituitary gland and craniopharyngeal duct	For craniopharyngeal duct tumors, select “Other endocrine including thymus” as the primary site of cancer.
237.1	Neoplasm of uncertain behavior (borderline) of the pineal gland	For pineal gland tumors, select “Other endocrine including thymus” as the primary site of cancer.
237.5	Neoplasm of uncertain behavior (borderline) of the brain and spinal cord	For spinal cord tumors, select “Central nervous system” as the primary site of cancer.
237.6	Neoplasm of uncertain behavior (borderline) of the meninges	

238.4	Polycythemia vera	
238.6	Plasma cells Plasmacytoma, extramedullary	
238.71	Essential thrombocythemia	
238.72	Refractory anemia Refractory anemia with ring sideroblasts Refractory neutropenia Refractory thrombocytopenia Refractory cytopenia with multilineage dysplasia	
238.73	Refractory anemia with excess blasts Refractory anemia with excess blasts in transformation	
238.74	Myelodysplastic syndrome with 5q-syndrome	
238.75	Myeloproliferative disease, NOS Therapy-related myelodysplastic syndrome	
238.76	Myelosclerosis with myeloid metaplasia	
238.77	Polymorphic post transplant lymphoproliferative disorder	
238.79	Other lymphatic and hematopoietic, which may include: Myeloid and lymphoid neoplasms with PDGFRA rearrangement Myeloid neoplasms with PDGFRB rearrangement Myeloid and lymphoid neoplasms with FGFR1 abnormalities Acute panmyelosis with myelofibrosis Fibroblastic reticular cell tumor Myelodysplastic/myeloproliferative neoplasm unclassifiable Chronic myeloproliferative disease, NOS	Note: for myelodysplastic/myeloproliferative neoplasm, select "Myeloproliferative, NOS."
239.6	Neoplasms of unspecified nature of the brain	
239.7	Neoplasms of unspecified nature of cerebral meninges or cranial nerves	
259.2	Carcinoid Syndrome	If this is diagnosed, review the medical record and report the primary site and histology.
273.2	Gamma heavy chain disease Franklin disease Mu-chain disease	Select "Heavy chain disease, NOS"
273.3	Waldenstrom macroglobulinemia	
288.3	Hypereosinophilic syndrome	288.3 is only reportable if listed as "Hypereosinophilic syndrome"
288.4	Langerhans cell histiocytosis, disseminated Langerhans cell histiocytosis, NOS	
289.6	Familial polycythemia	
289.83	Myelofibrosis as a result of myeloproliferative disease(a) Primary myelofibrosis (a) Idiopathic myelofibrosis(a) Acute myelofibrosis (b) Malignant myelofibrosis (b) Acute panmyelosis with myelofibrosis (b)	Review medical record as the term "myelofibrosis" may not necessarily be reportable. For (a) select "Myelosclerosis with myeloid metaplasia" from the list. For (b) select "Acute panmyelosis with myelofibrosis" from the list.